Shopping Cart
- Remove All
- Your shopping cart is currently empty
PI3Kα-IN-22 (Compound 17) is a potent, selective, and orally active inhibitor targeting the PI3Kα H1047R mutation, exhibiting an IC 50 of 1 nM in the pAKT T47D AlphaLISA assay. It has demonstrated the ability to induce tumor regressions in the HCC1954 tumor model in mice [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | PI3Kα-IN-22 (Compound 17) is a potent, selective, and orally active inhibitor targeting the PI3Kα H1047R mutation, exhibiting an IC 50 of 1 nM in the pAKT T47D AlphaLISA assay. It has demonstrated the ability to induce tumor regressions in the HCC1954 tumor model in mice [1]. |
Molecular Weight | 467.47 |
Formula | C24H23F2N5O3 |
Cas No. | 2925030-26-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.